Eavor demonstrates a disruptive and novel solution to many of the challenges that face geothermal energy production
CALGARY, Alberta, March 13, 2019 (GLOBE NEWSWIRE) -- Eavor Technologies Inc. (“Eavor”) is pleased to announce Shell International Exploration and Production, via its New Energies Research & Technology program, has signed an agreement to join a field trial of Eavor’s disruptive new closed-loop conduction-only geothermal energy solution (“Eavor-Loop™”). As part of the agreement, Shell will provide technical expertise towards the design of the drilling, completion, and facility construction of Eavor’s demonstration project (“Eavor-Lite™”), as well as a follow-on commercial implementation.
Eavor-Lite™ Demonstration Facility
The ten million-dollar ($10M CAD) demonstration project, Eavor-Lite, is designed to showcase all of Eavor’s unique and proprietary design elements at scale. The site, located near Rocky Mountain House, Alberta, will also be used as an ongoing test facility for advanced operating fluids being developed under Eavor’s ongoing R&D program. Drilling is to commence on Eavor-Lite™ in Q3 2019.
Eavor-Loop™ Full Scale Commercial Facility
Following successful completion of the demonstration facility, work will commence towards a commercial Eavor-Loop™ installation. While Eavor has a growing pipeline of such commercial power, heat, and combined heat+power opportunities from around the world, the first commercial Eavor-Loop project is expected to be a 65M EUR heat-only project in the Netherlands.
Why we’re working with Eavor
Malcolm Ross, the geothermal focus leader in the Shell New Energies Research & Technology team, explained the relevance of Eavor and its demonstration project. “In searching for the next breakthrough in geothermal energy, we at Shell came up with our top ten list of what was holding geothermal energy back. We recognized that Eavor-Loop™, and its unique conduction-only closed-loop design had the potential to address many of these concerns. That is why we’re supporting Eavor and their Eavor-Lite™ demonstration project.”
Why we’re working with Shell
“Working with Malcolm and his colleagues at Shell’s New Energies Research & Technology team has been extremely helpful,” said John Redfern, President & CEO of Eavor. “We appreciate Shell’s ability to look beyond conventional geothermal paradigms and see the potential of this completely new scalable form of geothermal energy. Eavor continues to seek out and work with progressive companies like Shell to leverage this technology on a global scale. Our goal is to convert the energy equivalent of ten million homes in ten years to the Eavor-Loop™ solution.”
About Eavor Technologies Inc.
Eavor’s solution (Eavor-Loop™) is designed to be the world's first truly scalable form of green baseload energy. It's a disruptive technology that eliminates or mitigates many of the issues with traditional geothermal. As a completely closed-loop system, there is no fracking, no GHG emissions (unlike some geothermal projects), no earthquake risk, no water use, no produced brine or solids, and no aquifer contamination. Eavor’s system circulates a benign working fluid which is isolated from the environment in a closed loop, much like a massive subsurface version of a traditional radiator. It simply collects heat from the natural geothermal gradient of the Earth, at geologically common rock temperatures. Unlike other green power solutions (e.g. wind and solar), Eavor-Loop™ is not intermittent, but instead produces much needed reliable baseload power. Unlike traditional geothermal, it isn't reliant on volcanic-like temperatures in combination with highly permeable aquifers. Eavor™ makes geothermal truly scalable and eliminates the major sources of exploratory cost and risk. For further information go to www.eavor.com and https://vimeo.com/301259525.
Eavor Technologies Inc.
President & CEO
A Media Snippet accompanying this announcement is available above and at https://ml.globenewswire.com/1.0/snippet/117/eng.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Blackhawks, Flyers, Sabres and Lightning Headline the 2019 NHL Global Series21.3.2019 15:34:00 CET | Pressemelding
Chicago Blackhawks and Philadelphia Flyers to Open Regular Season in Prague, Czech Republic on Oct. 4 Buffalo Sabres and Tampa Bay Lightning to Face Off in a Pair of Games in Stockholm, Sweden on Nov. 8 and Nov. 9 2019 NHL Global Series Challenge to feature Blackhawks vs. Eisbären Berlin on Sept. 29 in Berlin, Germany and Flyers vs. Lausanne HC on Sept. 30 in Lausanne, Switzerland Tickets to Games in Berlin, Prague and Stockholm Available for Purchase on Wednesday, March 27; Tickets to Game in Lausanne Available for Purchase on Wednesday, April 10 NEW YORK/TORONTO, March 21, 2019 (GLOBE NEWSWIRE) -- The National Hockey League (NHL) and the National Hockey League Players’ Association (NHLPA), in conjunction with Live Nation Sweden, today announced that the Buffalo Sabres, Chicago Blackhawks, Philadelphia Flyers and Tampa Bay Lightning will participate in the 2019 NHL Global Series. The Chicago Blackhawks and Philadelphia Flyers will play their 2019-20 season-opening game against each ot
Farmako: World's Largest Import Contract for Pharmaceutical Cannabis21.3.2019 15:10:00 CET | Pressemelding
German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP. Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years. Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored
NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in
Standard Lithium Announces Closing of $11.4 Million Bought Deal Including Partial Exercise of Over-Allotment Option21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”), including the partial exercise of the over-allotment option. A total of 11,390,500 units (the “Units”) of the Company were issued at a price of $1.00 per Unit for gross proceeds of $11,390,500. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.30 per share, subject to adjustment in certain events, until March 21, 2022. The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement
Crown Bioscience to Present Latest Advancements in Preclinical and Translational Platforms at AACR Annual Meeting 201921.3.2019 13:30:00 CET | Pressemelding
15 posters present data from novel models to evaluate new cancer therapeutics SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the presentation of 15 scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from March 29 to April 3. The scientific posters highlight the latest advancements in CrownBio’s integrated oncology and immuno-oncology platforms built on the world’s largest and unique experimental model libraries, including patient-derived xenografts (PDXs), innovative humanized mouse models, GEMM, syngeneic mouse tumor homografts, PDX derived organoids (PDXO), and uniquely developed analytic methods. Featured posters will present data from novel models that enable detailed evaluation of new cancer therapeutics, including targeted cancer i
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease21.3.2019 12:00:00 CET | Pressemelding
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease pa